maralixibat

01/01/2022 - "Conclusion: Maralixibat administration was associated with marked improvement in pruritus and QoL. "
01/01/2023 - "The significant improvements in pruritus seen with maralixibat at week 48 of the ICONIC study are clinically meaningful and are associated with improved HRQoL. "
01/01/2022 - "Maralixibat received its first approval on 29 September 2021, in the USA, for use in the treatment of cholestatic pruritus in patients with ALGS 1 year of age and older. "
10/30/2021 - "In the RWD, participants switched to placebo had significant increases in sBA (94 μmol/L, 95% CI 23 to 164) and pruritus (1·7 points, 95% CI 1·2 to 2·2), whereas participants who continued maralixibat maintained treatment effect. "
03/01/2019 - "Conclusion: Reductions in pruritus did not differ significantly between maralixibat and placebo. "

01/01/2023 - "Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life."
10/01/2018 - "Thirty-seven children with Alagille syndrome were randomly assigned to double-blinded administration of placebo, 70, 140, or 280 µg/kg/day of maralixibat for 13 weeks. "
10/30/2021 - "We evaluated the safety and efficacy of maralixibat for children with cholestasis in Alagille syndrome. "
01/01/2022 - "The current analyses combine two similar randomized placebo-controlled trials with subsequent extension phases investigating the impact of maralixibat in children with severe cholestasis secondary to Alagille Syndrome (n = 57). "
10/30/2021 - "Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study."

01/01/2022 - "Maralixibat relieves chronic cholestasis in children."
10/30/2021 - "We evaluated the safety and efficacy of maralixibat for children with cholestasis in Alagille syndrome. "
01/01/2022 - "The current analyses combine two similar randomized placebo-controlled trials with subsequent extension phases investigating the impact of maralixibat in children with severe cholestasis secondary to Alagille Syndrome (n = 57). "
01/01/2022 - "Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome."
10/30/2021 - "Maralixibat might represent a new treatment paradigm for chronic cholestasis in Alagille syndrome. "

01/01/2023 - "Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study."

03/01/2019 - "A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis."